LENZ Therapeutics, Inc. (NASDAQ:LENZ) Expected to Earn Q1 2024 Earnings of ($0.74) Per Share

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Analysts at William Blair issued their Q1 2024 earnings per share estimates for LENZ Therapeutics in a research report issued to clients and investors on Monday, April 15th. William Blair analyst T. Lugo expects that the company will earn ($0.74) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for LENZ Therapeutics’ Q2 2024 earnings at ($0.46) EPS, Q3 2024 earnings at ($0.46) EPS, Q4 2024 earnings at ($0.44) EPS, FY2024 earnings at ($2.10) EPS and FY2025 earnings at ($2.95) EPS.

A number of other research firms have also recently commented on LENZ. Piper Sandler began coverage on shares of LENZ Therapeutics in a report on Wednesday, March 27th. They issued an “overweight” rating and a $28.00 price target on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of LENZ Therapeutics in a research report on Monday. Citigroup started coverage on LENZ Therapeutics in a report on Wednesday, April 10th. They issued a “buy” rating and a $34.00 price target for the company. Finally, SVB Leerink began coverage on LENZ Therapeutics in a report on Monday. They set an “outperform” rating and a $32.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, LENZ Therapeutics presently has a consensus rating of “Buy” and an average target price of $31.33.

LENZ Therapeutics Stock Performance

Shares of LENZ Therapeutics stock opened at $17.49 on Wednesday. LENZ Therapeutics has a 52 week low of $14.07 and a 52 week high of $29.82. The firm has a market capitalization of $145.52 million, a price-to-earnings ratio of -1.12 and a beta of 0.20.

Insider Activity at LENZ Therapeutics

In related news, Director Ra Capital Management, L.P. purchased 998,009 shares of LENZ Therapeutics stock in a transaction dated Thursday, March 21st. The stock was purchased at an average cost of $15.03 per share, with a total value of $15,000,075.27. Following the transaction, the director now owns 3,319,339 shares in the company, valued at approximately $49,889,665.17. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 38.40% of the stock is currently owned by corporate insiders.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.